Kaplan Fox Calls for Beta Bionics Investors to Contact Firm
News related to:Beta Bionics, Inc · 2 min read
Kaplan Fox & Kilsheimer LLP, a national law firm, has issued a public call for Beta Bionics, Inc. (BBNX) investors who may have suffered financial losses due to alleged malfunctions in the company's iLet Bionic Pancreas insulin pump. The firm is representing a class action lawsuit filed against Beta Bionics, which claims the company received thousands of complaints, including reports of serious hypoglycemia incidents, during the period from July 30, 2025, to February 24, 2026.
According to the lawsuit, the root cause of these malfunctions is allegedly Beta Bionics’ aggressive dosing algorithm. This issue came to light after a series of disclosures. On January 8, 2026, the company reported a miss on the key metric of new iLet patient starts, causing a 37% one-day stock price decline. The situation worsened on February 24, 2026, when the U.S. Food and Drug Administration (FDA) publicly released a warning letter citing numerous violations and the company's failure to correct them. This contradicted months of public statements by Beta Bionics that all back-filed complaints were for benign issues.
The complaint alleges that Beta Bionics misrepresented the safety and effectiveness of the iLet Bionic Pancreas, leading to significant harm to patients. The lawsuit seeks to recover damages for investors who purchased or otherwise acquired Beta Bionics common stock during the class period. Kaplan Fox & Kilsheimer LLP is urging potential plaintiffs to contact the firm before November 3, 2026, to participate in the class action.
Kaplan Fox & Kilsheimer LLP, founded in 1956, is known for its expertise in complex litigation, particularly in securities, antitrust, and consumer protection cases. The firm has a track record of securing significant recoveries for its clients, including a $2.425 billion recovery for Bank of America shareholders and an $800 million settlement for the Arkansas Teacher Retirement System.
Investors who believe they may have suffered losses due to Beta Bionics’ alleged misconduct are encouraged to review their financial records and consider contacting Kaplan Fox & Kilsheimer LLP to learn more about their legal rights. The firm’s contact information is provided for those who wish to seek legal representation.